<TEXT>
T heincreasingcostofprescriptiondrugsintheUnitedStates hasbecomeasourceofgrowingconcernforpatients,pre- scribers,payers,andpolicymakers.Afterrelativelymod- estgrowthaftertheexpirationofpatentsonmanywidelyusedmedi- cationsfrom2010to2012,medicationexpenditureshavebegunto increaseagain,punctuatedbyseveralhigh-profileexamplesofvery costlynewagentsandsharpincreasesinthepricesofsomeolder ones.1 Between2013and2015,netspendingonprescriptiondrugs increasedapproximately20%intheUnitedStates,2 outpacingafore- cast11%increaseinaggregatehealthcareexpenditures.3 Prescrip- tionmedicationsnowcompriseanestimated17%oftotalhealthcare costs,4 andprescriptionmedicationcoverageconstitutes19%ofem- ployer-based insurance benefits.5 Since the advent of the Medi- care drug benefit in 2006, government entities have paid for ap- proximately 40% of the nation’s total retail prescription drug expenditure.6 Certainexpensivedrugproductsareimportantclini- cal breakthroughs and may even be relatively cost-effective; oth- ersaremerelycostly,withpricesthataredifficulttojustifyinrela- tiontotheiractualcontributionstopatientoutcomes. TheUnitedStateshaslongspentmoreonprescriptionmedi- cationsthanothercountries.7 In2013,percapitaspendingonpre- scriptiondrugswas$858comparedwithanaverageof$400for19 advancedindustrializednations(Figure1).8 Listpricesforthetop 20highest-revenue-grossingdrugswereonaverage3timesgreater intheUnitedStatesthantheUnitedKingdom.9 Thesedisparitiesare reduced but remain substantial even after accounting for undis- closed discounts (“rebates”) that manufacturers offer to US pay- ers.In2010,estimatedaveragepostrebatepricesformedications were10%to15%higherintheUnitedStatesthaninCanada,France, andGermany(Table1).11 In addition to their contribution to health care spending, in- creasing drug costs have important clinical implications. Because cost-containment efforts require patients to pay higher co- paymentsfortheirmedications,suchincreasescanreducetheaf- fordabilityofprescribedregimensandthuspatientadherence,lead- ingtonegativehealthoutcomes.12 However,somecostlydrugsmay offerreasonablevalue.Forexample,sofosbuvir(Sovaldi)wasfound tobeacost-effectivetreatmentofhepatitisCinfectionevenatits 2013 launch price of $84000 per 12-week course in certain pa- tientpopulationswhenviewedfromapatient’slifetimehorizonand a societal perspective.13 Payers must pay for this treatment up- front,though,withhealthcarebenefitsoftenaccruingdecadeslater
</TEXT>
<FORM>
Table1.ExamplesofCountry-SpecificAverageDrugPricesforTop-SellingDrugsin2015
                                        MonthlyPrice,US$
                                        UnitedStates
                                        Nondis-       Estimated
                                        counted       Discounted
 Drug                                   Price         Price         Canada        France       Germany
 Adalimumab(Humira),40mgbiweekly         3430.82       2504.50       1164.32        981.79       1749.26
 Fluticasone/salmeterol(Advair),250μg,     309.60       154.80          74.12         34.52        37.71
 50μgdaily
 Insulinglargine(Lantus),50insulin         372.75       186.38          67.00         46.60        60.90
 unitsdaily
 Rosuvastatin(Crestor),10mgdaily           216.00         86.40         32.10         19.80        40.50
 Sitagliptin(Januvia),100mgdaily           330.60       168.61          68.10         35.40        39.00
 Sofosbuvir(Sovaldi),400mgdaily         30000.00      17700.00      14943.30      16088.40     17093.70
 Trastuzumab(Herceptin),                 5593.47       4754.45                     2527.97       3185.87
 450mgevery3wk
</FORM>
<CAPTION>
Figure1.PerCapitaSpendingonPrescriptionPharmaceuticals
</CAPTION>
<CAPTION>
Copyright 2016 American Medical Association. All rights reserved. Copyright 2016 American Medical Association. All rights reserved.
</CAPTION>
<PAGE_FOOTER>
859
</PAGE_FOOTER>
<PAGE_FOOTER>
JAMA August23/30,2016 Volume316,Number8
</PAGE_FOOTER>
<PAGE_FOOTER>
Downloaded From: http://jama.jamanetwork.com/ by a University of Florida User on 09/13/2016
</PAGE_FOOTER>
<PAGE_HEADER>
TheHighCostofPrescriptionDrugsintheUnitedStates
</PAGE_HEADER>
<PAGE_HEADER>
SpecialCommunication ClinicalReview&Education
</PAGE_HEADER>
<UNSPECIFIED>
                                                                                                           Source:BloombergBusinessreport
                                                                                                           andSSRHealth.10
jama.com                                                                          (Reprinted)
</UNSPECIFIED>
<PAGE_BREAK>
